TOTM
The NIH ‘Access Plan’ Mandate: Central Planning by Another Name
Truth on the Market
View Original Source
When the National Institutes of Health (NIH) announced in July that it would move forward with a Biden-era proposal to require “access plans” for companies seeking to license NIH-owned patents, the decision stunned many in the innovation community. Industry groups warned that this new bureaucratic hurdle would “kill NIH licensing.”
They’re right, and not merely in a practical sense. The policy’s very design embodies the fatal conceit that government planners can anticipate and orchestrate the countless market interactions that drive innovation.